| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.
- Study Design:
- Tumor vs. Matched-Normal
- Study Type:
- Cohort
- Tumor vs. Matched-Normal
- Total number of consented subjects: 34
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Inclusion: non-small cell lung cancer, treated with pembrolizumab
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Exome Sequencing Illumina HiSeq 2000 N/A N/A Paired-end reads,2x76bp - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Carcinoma, Non-Small-Cell Lung
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigators
- Timothy Chan, MD, PhD. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Matthew Hellmann, MD. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
-
Funding Sources
- Geoffrey Beene Cancer Research Center. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Society for Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Frederick Adler Chair Fund. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- The STARR Foundation. Starr Cancer Consortium, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant. Cancer Research Institute, New York, NY, USA.
-
Principal Investigators